Pathophysiological Aspects and Therapeutic Approaches of Tumoral Osteolysis and Hypercalcemia

  • J. P. Bonjour
  • R. Rizzoli
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 116)


Numerous malignant tumors can affect the skeleton and disturb the homeostasis of both calcium (Ca) and inorganic phosphate (Pi), the two main constituents of bone mineral (Rodman and Sherwood 1978; Mundy and Martin 1982). The clinical consequences of these disturbances can be dramatic on the degree of morbidity of cancer patients. Bone metastasis and osteolysis are a major source of pain, pathological fractures, and disability. Hypercalcemia is associated with nausea, vomiting, dehydration, mental disturbance, confusion, and eventually coma. The appropriate management of tumor-mediated bone osteolysis and hypercalcemia requires an appreciation of the various factors implicated in bone remodeling and in Ca homeostasis (Mundy and Roodman 1987; Bonjour et al. 1987).


Bone Resorption Tubular Reabsorption Leydig Cell Tumor Renal Reabsorption Renal Tubular Reabsorption 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Binstock ML, Mundy GR (1980) Effect of calcitonin and glucocorticoids in combination on the hypercalcemia of malignancy. Ann Intern Med 93: 269–272.PubMedGoogle Scholar
  2. Bockman RS, Boskey A, Alcock N, Bullough P, Warrell R (1986) Gallium nitrate inhibits bone resorption, increases bone calcium content but is not cytotoxic to bone cells (abstract). J Bone Min Res 1: 65.Google Scholar
  3. Bonjour JP, Philippe J, Guelpa G, Bisetti A, Rizzoli R, Jung A, Rosini S (1985) Bone and renal components in hypercalcemia of malignancy (HM) evaluated in relation with the therapeutical response to one single infusion of clodronate. Calcif Tissue Int 38 [Suppl]: S32.Google Scholar
  4. Bonjour JP, Rizzoli R, Hirschel-Scholz S, Caverzasio J (1987) Management of hypercalcemia in relation to pathophysiology. Bone 8 [Suppl 1]: S29–S33.PubMedGoogle Scholar
  5. Bonjour JP, Philippe J, Guelpa G, Bisetti A, Rizzoli R, Jung A, Rosini S, Kanis JA (1988) Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate. Bone 9: 123–130.PubMedCrossRefGoogle Scholar
  6. Breslau NA, McGuire JL, Zerwekh JE, Frenkel EP, Pak CYC (1984) Hypercalcemia associated with increased serum calcitriol levels in three patients with lymphoma. Ann Intern Med 100: 1–7.PubMedGoogle Scholar
  7. Fleisch H (1983) Bisphosphonates: mechanisms of action and clinical applications. In: Peck WA (ed) Bone and mineral research/1. Excerpta Medica, Amsterdam, pp 319–357.Google Scholar
  8. Fleisch H (1987) Bisphosphonates — history and experimental basis. Bone 8 [Suppl 1]: S23–S28.PubMedCrossRefGoogle Scholar
  9. Hirschel-Scholz S, Bonjour JP (1987) Radioprotective agent WR-2721 opens new perspective in treatment of hyperparathyroidism and hypercalcemia. Trend Pharmacol Sci 8: 246–247.CrossRefGoogle Scholar
  10. Hirschel-Scholz S, Caverzasio J, Bonjour JP (1985) Inhibition of parathyroid hormone (PTH) secretion and PTH-independent diminution of tubular Ca reabsorption by WR-2721, a unique hypocalcemic agent. J Clin Invest 76: 1851–1856.PubMedCrossRefGoogle Scholar
  11. Hirschel-Scholz S, Caverzasio J, Rizzoli R, Bonjour JP (1986) Normalization of hypercalcemia associated with a decrease in renal calcium reabsorption in Leydig cell tumor-bearing rats treated with WR-2721. J Clin Invest 78: 319–322.PubMedCrossRefGoogle Scholar
  12. Horiuchi N, Caulfield MP, Fisher JE, Goldman ME, McKee RL, Reagan JE, Levey JJ, Nutt RF, Rodan SB, Schofield TL, Clemens TL, Rosenblatt M (1987) Similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro. Science 238: 1566–1570.PubMedCrossRefGoogle Scholar
  13. Hosking DJ, Gilson D (1984) Comparison of the renal and skeletal actions of calcitonin in the treatment of severe hypercalcemia of malignancy. Q J Med 211: 359–368.Google Scholar
  14. Hosking DJ, Cowley A, Bucknall CA (1981) Rehydration in the treatment of severe hypercalcaemia. Q J Med 200: 473–481.Google Scholar
  15. Jung A (1982) Comparison of two parenteral diphosphonates in hypercalcemia of malignancy. Am J Med 72: 221–227.PubMedCrossRefGoogle Scholar
  16. Ljunghall S, Rastad J, Akerstrom G (1987) Comparative effects of calcitonin and clodronate in hypercalcaemia. Bone 8 [Suppl 1]: S79–S83.PubMedGoogle Scholar
  17. Martodam RR, Thornton KS, Sica DA, D’Souza SM, Flora L, Mundy GR (1983) The effects of dichloromethylene diphosphonate on hypercalcemia and other parameters of the humoral hypercalcemia of malignancy in the rat Leydig cell tumor. Calcif Tissue Int 35: 512–519.PubMedCrossRefGoogle Scholar
  18. McSheehy PMJ, Chambers TJ (1986) Osteoblastic cells mediate osteoclastic responsiveness to parathyroid hormone. Endocrinology 118: 824–828.PubMedCrossRefGoogle Scholar
  19. Moseley JM, Kubota M, Diefenbach-Jagger H, Wettenhall REH, Kemp BE, Suva LJ, Rodda CP, Ebeling PR, Hudson PJ, Zajac JD, Martin TJ (1987) Parathyroid hormonerelated protein purified from a human lung cancer cell line. Proc Natl Acad Sci USA 84: 5048–5052.PubMedCrossRefGoogle Scholar
  20. Mundy GR (1987) Bone resorption and turnover in health and disease. Bone 8 [Suppl 1]: S9–S16.PubMedGoogle Scholar
  21. Mundy GR, Martin TJ (1982) The hypercalcemia of malignancy. Pathogenesis and management. Metabolism 31: 1247–1277.PubMedCrossRefGoogle Scholar
  22. Mundy GR, Roodman GD (1987) Osteoclast ontogeny and function. In: Peck WA (ed) Bone and mineral research/5. Elsevier, Amsterdam, pp 209–279.Google Scholar
  23. Percival RC, Yates AJP, Gray RES, Galloway J, Rogers K, Neal FE, Kanis JA (1985) Mechanism of malignant hypercalcaemia in carcinoma of the breast. Br Med J 291: 776–779.CrossRefGoogle Scholar
  24. Pizurki L, Rizzoli R, Caverzasio J, Bonjour JP (1987) Specific inhibition by parathyroid hormone-like factor(s) produced by human lung squamous-cell carcinoma of sodium-dependent phosphate transport in cultured renal epithelium. J Bone Min Res 2 [Suppl 1]: 393 (Abstract).Google Scholar
  25. Pizurki L, Rizzoli R, Moseley J, Martin TJ, Caverzasio J, Bonjour JP (1988) Effect of synthetic tumoral parathyroid hormone related peptide on cAMP production and sodiumdependent phosphate transport in cultured renal cells epithelia (abstract). Calcif Tissue Int 42 [Suppl 2]: A46.Google Scholar
  26. Ralston SH, Dryburgh FJ, Cowan RA, Gardner MD, Jenkins AS, Boyle IT (1985) Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia. Lancet 2: 907–910.PubMedCrossRefGoogle Scholar
  27. Rizzoli R, Caverzasio J, Fleisch H, Bonjour JP (1986) Parathyroid hormone-like changes in renal calcium and phosphate reabsorption induced by Leydig cell tumor in thyroparathyroidectomized rats. Endocrinology 119: 1004–1009.PubMedCrossRefGoogle Scholar
  28. Rizzoli R, Caverzasio J, Moseley J, Martin TJ, Vadas L, Bonjour JP (1988) Synthetic tumoral parathyroid hormone related peptide (PTHrP(1–34)) stimulates the renal tubular reabsorption of calcium (TRCa) (abstract). J Bone Min Res 3 [Suppl 1]: no. 13.Google Scholar
  29. Rodman JS, Sherwood LM (1978) Disorders of mineral metabolism in malignancy. In: Avioli LV, Krane SM (eds) Metabolism bone diseases. Academic, New York, pp 577–631.Google Scholar
  30. Stewart AF, Burtis WJ, Wu T, Goumas D, Broadus AE (1987) Two forms of parathyroid hormone-like adenylate cyclase-stimulating protein derived from tumors associated with humoral hypercalcemia of malignancy. J Bone Min Res 2: 587–593.CrossRefGoogle Scholar
  31. Strewler GJ, Stern PH, Jacobs JW, Eveloff J, Klein RF, Leung SC, Rosenblatt M, Nissenson RA (1987) Parathyroid hormone-like protein from human renal carcinoma cells. Structural and functional homology with parathyroid hormone. J Clin Invest 80: 1803–1807.PubMedCrossRefGoogle Scholar
  32. Suva LJ, Winslow GA, Wettenhall REH, Hammonds RG, Moseley JM, Diefenbach-Jagger H, Rodda CP, Kemp BE, Rodriguez H, Chen EY, Hudson PJ, Martin TJ, Wood WI (1987) A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 237: 893–896.PubMedCrossRefGoogle Scholar
  33. Warrell RP Jr, Skelos A, Alcock NW, Bockman RS (1986) Gallium nitrate for acute treatment of cancer-related hypercalcemia: clinicopharmacological and dose response analysis. Cancer Res 46: 4208–4212.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • J. P. Bonjour
    • 1
  • R. Rizzoli
    • 1
  1. 1.Division of Clinical Pathophysiology, Department of MedicineUniversity HospitalGeneva 4Switzerland

Personalised recommendations